Cambrex expands in analytics
API and finished dosage form manufacturer Cambrex is investing $1 million at its site in High Point, North Carolina, in response to a growing number of new projects. In total, it will fit out 120 m2 of analytical laboratory space and will hire nine chemical R&D and six analytical R&D scientists, as well as installing ten ultra-performance liquid chromatography (UPLC) instruments.
The fit-out and expansion is expected to be completed by the end of the year. It follows on from a $3.2 million investment in a 1,020 m2 analytical laboratory, which was completed in April 2018. This brings to $9 million the level of investment by Cambrex at High Point, which was acquired as part of the former PharmaCore in 2016 and which produces complex APIs and intermediates requiring multi-step synthetic processes in batches from mg to up to 100 kg for Phase I-II clinical trials